Dear Health Care Professional,
Pfizer is pleased to inform you that the QuilliChew ER (methylphenidate HCl) chewable tablet supply issue has been resolved and QuilliChew ER is available to patients as appropriate.
As for Quillivant XR (methylphenidate HCI) oral suspension, there is still supply shortage for this product. Pfizer is working diligently to resolve the supply, however the duration of the supply shortage is unknown at this time. In the interim, health care professionals should use their clinical expertise to determine the best treatment for their patients.
Pfizer realizes that this disruption may cause concern for you and your patients, and we sincerely apologize for this disruption. Pfizer will send out another alert once Quillivant XR is back in adequate supply at our wholesalers. We appreciate your patience and understanding as we work to resolve this issue.
Health care providers are encouraged to report adverse events, including product defects, by contacting Pfizer Medical Information at 1-800-438-1985 or by contacting the FDA at http://www.fda.gov/Safety/MedWatch or by calling 1-800-FDA-1088.
If you have any medical inquiries regarding Quillivant XR or QuilliChew ER, please contact Pfizer Medical Information at 1-800-438-1985.
Please see accompanying full Prescribing Information, including BOXED WARNING for Quillivant XR and QuilliChew ER.
PP-QCH-USA-0205 ©2018 Pfizer Inc. All rights reserved. Printed in USA/January 2018